GlassScriptPhysician profile
Juan Weksler
NPI 1316919723
$3,773.56
in general payments reported to CMS, 2019-2025
23 companies · $756 in 2025
The $756 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $61.82 · 2021: $1,064 · 2022: $842 · 2023: $304 · 2024: $417 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,477.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $940.55 | 2019-2022 | |
| Shockwave Medical, INC | $534.74 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $439.18 | 2023-2025 | Onyx Frontier, Symplicity G3 |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $342.73 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $221.99 | 2019 | |
| Boston Scientific Corporation | $188.12 | 2020-2025 | Eluvia |
| Novartis Pharmaceuticals Corporation | $175.04 | 2019-2025 | |
| Biotronik INC. | $134.64 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $120.82 | 2020-2025 | Eliquis, Camzyos |
| Inari Medical, INC. | $119.06 | 2022 | |
| W. L. Gore & Associates, INC. | $92.63 | 2022 | |
| Pfizer INC. | $91.35 | 2024-2025 | |
| Bridgebio Pharma, INC. | $80.67 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals LP | $77.59 | 2021-2025 | Wainua |
| Abiomed | $35.28 | 2024-2025 | Impella |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $32.75 | 2022-2025 | Repatha |
| Philips North America LLC | $32.30 | 2020 | |
| Bard Peripheral Vascular, INC. | $32.27 | 2019 | |
| Cardiva Medical, INC. | $20.28 | 2019 | |
| Scpharmaceuticals INC. | $18.74 | 2025 | |
| Terumo Medical Corporation | $16.33 | 2023 | Azur Cx Detachable |
| Lilly USA, LLC | $14.37 | 2025 | Zepbound, Mounjaro |
| Davol INC. | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Weksler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.